Min-Han Tan, CEO and Medical Director at Lucence, shared a post on LinkedIn:
“Singapore once spoke about becoming the “Mayo of the East” in 2003. The path eventually taken was different.
Rather than replicating an institution, Singapore invested in biomedical capabilities, with early leadership from Philip Yeo.
Two decades on, that investment is evident.
Technology developed in Singapore is now being adopted by leading global institutions.
Liquid HALLMARK, a Medicare-covered liquid biopsy test combining ctDNA and ctRNA, is offered in the United States in collaboration with Mayo Clinic Laboratories – with appreciation to William Morice II and Chris Chong for their leadership and collaboration.
From aspiration to adoption. Precision health in clinical practice.”
Other articles featuring Min-Han Tan on OncoDaily.